Please assess the completion status of the following clinical trial:

Trial Title: A Research Called CREDIT Studies How Safe the Study Treatment Radium-223 is and How Well it Works in Chinese Men With Advanced Prostate Cancer That Has Spread to the Bones and Does Not Respond to Treatments for Lowering Testosterone Levels

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Male patient~* Histologically or cytologically confirmed castration resistant adenocarcinoma of the prostate with bone metastases~* No visceral metastases~* Decision to initiate treatment with Radium-223 was made independently prior to patient enrollment in the study as per investigator's routine treatment practice~* Signed informed consent~Exclusion Criteria:~* Patients previously treated with Radium-223 for any reason~* Patients currently treated in any other clinical trials including other Radium-223 studies~* Patients are planned for the systemic concomitant use of other radiopharmaceuticals for treatment of prostate cancer or for other use~* Participation in an investigational program with interventions outside of routine clinical practice~* Patients previously treated with Docetaxel~* Patients under treatment with Abiraterone Acetate and the Corticosteroids Prednisone or Prednisolone~Besides Inclusion and exclusion criteria, sites should also follow the locally approved Radium-223 product information

- Gender: MALE
- Minimum Age: None
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Radium-223 dichloride treatment (Type: None): Castration-resistant prostate cancer (CRPC) patients with bone metastases for whom a decision has been made independently by the treating physician and the patient to treat with Radium-223.

Based on this trial design, predict the completion outcome and termination type (if applicable).